Literature DB >> 12838339

Phospholamban: a crucial regulator of cardiac contractility.

David H MacLennan1, Evangelia G Kranias.   

Abstract

Heart failure is a major cause of death and disability. Impairments in blood circulation that accompany heart failure can be traced, in part, to alterations in the activity of the sarcoplasmic reticulum Ca2+ pump that are induced by its interactions with phospholamban, a reversible inhibitor. If phospholamban becomes superinhibitory or chronically inhibitory, contractility is diminished, inducing dilated cardiomyopathy in mice and humans. In mice, phospholamban seems to encumber an otherwise healthy heart, but humans with a phospholamban-null genotype develop early-onset dilated cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12838339     DOI: 10.1038/nrm1151

Source DB:  PubMed          Journal:  Nat Rev Mol Cell Biol        ISSN: 1471-0072            Impact factor:   94.444


  381 in total

1.  Force relaxation and thin filament protein phosphorylation during acute myocardial ischemia.

Authors:  Young Soo Han; Ozgur Ogut
Journal:  Cytoskeleton (Hoboken)       Date:  2010-11-02

2.  Decreased polycystin 2 expression alters calcium-contraction coupling and changes β-adrenergic signaling pathways.

Authors:  Ivana Y Kuo; Andrea T Kwaczala; Lily Nguyen; Kerry S Russell; Stuart G Campbell; Barbara E Ehrlich
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

Review 3.  A-kinase anchoring proteins that regulate cardiac remodeling.

Authors:  Graeme K Carnegie; Brian T Burmeister
Journal:  J Cardiovasc Pharmacol       Date:  2011-11       Impact factor: 3.105

4.  Phospholamban mutants compete with wild type for SERCA binding in living cells.

Authors:  Simon J Gruber; Suzanne Haydon; David D Thomas
Journal:  Biochem Biophys Res Commun       Date:  2012-03-01       Impact factor: 3.575

5.  Functional and physical competition between phospholamban and its mutants provides insight into the molecular mechanism of gene therapy for heart failure.

Authors:  Elizabeth L Lockamy; Razvan L Cornea; Christine B Karim; David D Thomas
Journal:  Biochem Biophys Res Commun       Date:  2011-04-12       Impact factor: 3.575

Review 6.  Cardiovascular gene therapy for myocardial infarction.

Authors:  Maria C Scimia; Anna M Gumpert; Walter J Koch
Journal:  Expert Opin Biol Ther       Date:  2013-12-16       Impact factor: 4.388

7.  Cardiomyocytes from AKAP7 knockout mice respond normally to adrenergic stimulation.

Authors:  Brian W Jones; Sylvain Brunet; Merle L Gilbert; C Blake Nichols; Thomas Su; Ruth E Westenbroek; John D Scott; William A Catterall; G Stanley McKnight
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-03       Impact factor: 11.205

8.  Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

Authors:  Lennart Suckau; Henry Fechner; Elie Chemaly; Stefanie Krohn; Lahouaria Hadri; Jens Kockskämper; Dirk Westermann; Egbert Bisping; Hung Ly; Xiaomin Wang; Yoshiaki Kawase; Jiqiu Chen; Lifan Liang; Isaac Sipo; Roland Vetter; Stefan Weger; Jens Kurreck; Volker Erdmann; Carsten Tschope; Burkert Pieske; Djamel Lebeche; Heinz-Peter Schultheiss; Roger J Hajjar; Wolfgang C Poller
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

9.  Activation of ryanodine receptors induces calcium influx in a neuroblastoma cell line lacking calcium influx factor activity.

Authors:  Diptiman D Bose; Roshanak Rahimian; David W Thomas
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

10.  Discovery of enzyme modulators via high-throughput time-resolved FRET in living cells.

Authors:  Simon J Gruber; Razvan L Cornea; Ji Li; Kurt C Peterson; Tory M Schaaf; Gregory D Gillispie; Russell Dahl; Krisztina M Zsebo; Seth L Robia; David D Thomas
Journal:  J Biomol Screen       Date:  2014-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.